Identify the denominator behind each percentage
A chromatographic area result compares the integrated signal assigned to a main peak with the relevant integrated signals under that procedure. Peptide content concerns the peptide fraction of the supplied material under a stated definition and analytical method. Gross powder mass includes the material as weighed. These figures should occupy separate fields in a technical specification.
An instructive published example comes from Bachem’s care and handling note: it describes research peptides above 95% HPLC purity whose peptide content may fall between 70% and 90% because the solid also contains counterions and moisture. That is a supplier’s technical example, not a universal range or a claim about products on this site. Obtain the supplied lot’s own results.
Put the method identifier beside each result in a comparison sheet. Reserve a separate column for the reporting basis, such as chromatographic area or a specified mass fraction. A percentage without that basis is an unresolved field, even when it looks better than a competing offer.
| Reported item | Purchasing question | Do not assume |
|---|---|---|
| HPLC area purity | Which peaks and method define the percentage? | It equals peptide mass fraction |
| Peptide content | What does the method count as peptide? | Every laboratory uses the same definition |
| Gross mass | Is the order priced on supplied powder? | All of that mass is target peptide |
| Identity result | Which molecular form was compared? | Identity establishes quantity or sterility |
Compare quantities on a stated basis
Consider a hypothetical purchasing file containing 10.00 mg of supplied powder and an independently reported peptide content of 82.0% by mass. If that content definition is the basis agreed in the specification, the corresponding peptide mass is 10.00 mg multiplied by 0.820, or 8.20 mg. This arithmetic illustrates the unit conversion; it is not a batch result, a product specification or a dosing instruction.
Do not substitute an HPLC area percentage for the 82.0% mass fraction. Also ask whether the content method measures total peptidic material or the target component specifically. Multiplying two percentages without understanding their definitions can produce a precise-looking quantity that neither laboratory report supports. Quotations for peptide raw materials should state whether the commercial quantity refers to gross supplied mass or another agreed basis.
For a commercial comparison, retain the original quotation quantity and show any agreed calculation on a separate line. The unit should remain visible at each step. This makes the example reproducible and avoids silently replacing a supplier’s declared quantity with a buyer’s interpretation.
Fields to place next to the quotation quantity
- Gross supplied mass and its unit.
- Content result, method and calculation basis when required.
- Chromatographic purity result and procedure identifier.
- Counterion and water results where specified.
- Any proposed adjustment to the invoiced quantity.
Ask for method context before comparing laboratories
Two laboratories can report different percentages while testing the same material because the procedures, integration rules or reporting bases differ. Resolve those differences through the quality contacts before deciding that one result disproves the other. Request the approved method identifier and a written explanation of what the result includes. A screenshot with the peak labels cut off makes that review harder.
ICH Q2(R2) provides a framework for demonstrating analytical fitness for purpose. It discusses performance characteristics including specificity/selectivity, accuracy and precision. These pharmaceutical validation principles are useful context for a technical discussion; citing them does not establish that a particular research-material method has been validated. The supplier must provide evidence appropriate to the measurement it claims.
A proposed comparison file can retain both original reports, the method versions and a short laboratory reconciliation. Decide the acceptance method before commissioning a retest. Choosing whichever result is higher after both reports arrive leaves the purchasing decision without a consistent technical basis.
Keep identity evidence separate from content
Mass spectrometry reports ion-related measurements. The IUPAC Gold Book entry for m/z defines the term through an ion’s mass number and charge number. A displayed m/z value should therefore be interpreted with the reported ion assignment and charge state; it should not be copied into a molecular-weight field without explanation.
Ask the laboratory to identify the theoretical comparison, observed result and acceptance basis. If a result is described as a deconvoluted mass, keep that description. A single mass match should not be presented as a complete sequence or impurity assessment. The necessary identity evidence depends on the material and the purchasing risk. The supplied-form specification should keep the molecular description consistent across the quotation and analytical records.
Keep the identity conclusion and the underlying measurement in separate fields. For example, the issued report may give an observed ion, a charge assignment and a comparison with a theoretical value. Preserve those labels when summarising the result for a purchasing reviewer.
Write acceptance criteria before receiving the lot
Use separate acceptance lines for identity, chromatographic purity and content whenever those measurements are required. Do the same for water, counterions or residual solvents where the project specification calls for them. A blank result means the information has not been supplied; a “pass” without a stated criterion leaves the reviewer unable to reproduce the decision.
For a failed comparison, record the sample and lot, procedure version, result unit and disputed point. Ask for an authorised laboratory explanation rather than recalculating a COA to fit the purchase order. See the supplier evidence checklist for the surrounding document chain. This article concerns research procurement and analytical interpretation, not clinical use or product release for patient treatment.
The purchase specification should also say what happens when a required result is missing. Set out the escalation contact and the evidence needed to close the gap. A receiving hold can then be lifted by a recorded decision rather than an informal correction to a spreadsheet.
Frequently asked questions
Can 99% HPLC purity mean 99% of the vial’s weight is peptide?
That conclusion needs a separate mass-based measurement and an agreed definition. HPLC area purity alone does not establish the peptide mass fraction of the supplied solid.
Should I multiply peptide content by HPLC purity?
Only if the laboratory’s definitions and the agreed calculation specifically support that operation. Content methods can measure different quantities; automatic multiplication can double-count a correction.
Does a matching mass spectrum prove sterility?
No. Mass-related identity evidence does not establish sterility, endotoxin status or a complete impurity profile. Those require separately defined evidence when relevant.
Can the worked 82% example be used for a real order?
No. It is an illustrative arithmetic example. Use the actual lot’s measured content, its method definition and the signed purchasing specification.
Sources and editorial basis
References checked on 31 October 2026. The checklists and examples are editorial procurement guidance. Pharmaceutical standards are cited for their stated scope; they do not certify this supplier, a research material or a shipment.
Scope: B2B research-material procurement. This article provides no dosing, treatment or human-use instructions. Product-specific acceptance requires the signed specification and actual lot records.
Request a specification and document review with the material identifier, supplied form, quantity basis and destination. Availability and test scope require project confirmation.